Log In Sign up
The largest database of trusted experimental protocols

Xl413

Manufactured by Selleck Chemicals
Visit Supplier
Sourced in Germany, United States

The XL413 is a lab equipment product designed for general laboratory use. It is a versatile device that can be utilized for various experimental and analytical purposes. The core function of the XL413 is to perform precise measurements and data collection. No further details about its intended use or applications are provided.

Automatically generated - may contain errors

Lab products found in correlation

Ab2426, by Abcam (2 mentions) Ab77668, by Abcam (2 mentions) Mk 8776, by Selleck Chemicals (2 mentions) Thz531 a8736, by Apexbio (2 mentions) Tak 931 ct tak931, by Chemietek (2 mentions) Ab62322, by Abcam (2 mentions) Egfr antibody 610017, by BD (2 mentions) Bi2536, by Selleck Chemicals (2 mentions) Etoposide, by Selleck Chemicals (2 mentions) Doxycycline, by Merck Group (2 mentions) Azd7762, by Selleck Chemicals (1 mentions) Alisertib, by Selleck Chemicals (1 mentions) Cct245737, by Selleck Chemicals (1 mentions) Cisplatin ddp, by Selleck Chemicals (1 mentions) Ucn 01, by Merck Group (1 mentions) Roscovitine, by Selleck Chemicals (1 mentions) Auxin 3 indoleacetic acid, by Merck Group (1 mentions) Chir 124, by Selleck Chemicals (1 mentions) Cdk1 2 inhibitor 3, by Merck Group (1 mentions) Sb202190, by Selleck Chemicals (1 mentions)

8 protocols using xl413

1

Inhibitors Targeting Cellular Signaling

Check if the same lab product or an alternative is used in the 5 most similar protocols
XL413 (S7547), BMS265246 (S2014), ON-01910 (S1362), PD0166285 (S8148), LDC000067 (S7461), PF-03814735 (S2725), D 4476 (S7642), VE-821 (S8007), AZD8055 (S1555), AZD2014 (S2783), AZD6738 (S7693) and MK-8776 (2735) were purchased from Selleck Chemicals. THZ531 (A8736) was purchased from ApexBio. XL413 (205768), BLU9931 (206192) and LY3177833 (206762) were purchased from MedKoo. TAK-931 (CT-TAK931) was purchased from Chemietek. XL413 (A13677) was also purchased from AdooQ BIOSCIENCE. The SHP2 inhibitor used in this study is covered by a patent application (WO 2015/107495A1; compound #57) and was synthesized as described previously23 (link).
Antibodies against HSP90 (sc-7947, sc-13119), p53 (sc-126), p21 (sc-6246), and SHP2 (sc-280) were purchased from Santa Cruz Biotechnology. Antibodies against CDC7 (ab77668), p-MCM2 (ab109133, ab133243), MCM2 (ab4461), p-SHP2 (ab62322), PCNA (ab2426), and Cleaved caspase-3 (ab2303) were purchased from Abcam. Antibodies against γH2AX (#9718), p-S6RP (#4856, #5364), S6RP (#2317), p-4EBP1 (#9456, #2855, #9455), 4EBP1 (#9644), p-IGF-1R/INSR (#3024), IGF-1R (#9750), p-PDGFRβ (#3161), PDGFRβ (#4564), p-AKT (#4060), and AKT (#2920) were purchased from Cell Signalling. EGFR antibody (610017) was purchased from BD Biosciences. H3K9Me3 antibody (49-1008) and p-EGFR (44-788) were from Thermo Fisher Scientific.
Wang C., Vegna S., Jin H., Benedict B., Lieftink C., Ramirez C., Leite de Oliveira R., Morris B., Gadiot J., Wang W., du Chatinier A., Wang L., Gao D., Evers B., Jin G., Xue Z., Schepers A., Jochems F., Mulero Sanchez A., Mainardi S., te Riele H., Beijersbergen R.L., Qin W., Akkari L, & Bernards R. (2019). Inducing and exploiting vulnerabilities for the treatment of liver cancer. Nature, 574(7777), 268-272.
+ Open protocol
+ Expand
2

Inhibitors Targeting Cellular Signaling

Check if the same lab product or an alternative is used in the 5 most similar protocols
XL413 (S7547), BMS265246 (S2014), ON-01910 (S1362), PD0166285 (S8148), LDC000067 (S7461), PF-03814735 (S2725), D 4476 (S7642), VE-821 (S8007), AZD8055 (S1555), AZD2014 (S2783), AZD6738 (S7693) and MK-8776 (2735) were purchased from Selleck Chemicals. THZ531 (A8736) was purchased from ApexBio. XL413 (205768), BLU9931 (206192) and LY3177833 (206762) were purchased from MedKoo. TAK-931 (CT-TAK931) was purchased from Chemietek. XL413 (A13677) was also purchased from AdooQ BIOSCIENCE. The SHP2 inhibitor used in this study is covered by a patent application (WO 2015/107495A1; compound #57) and was synthesized as described previously23 (link).
Antibodies against HSP90 (sc-7947, sc-13119), p53 (sc-126), p21 (sc-6246), and SHP2 (sc-280) were purchased from Santa Cruz Biotechnology. Antibodies against CDC7 (ab77668), p-MCM2 (ab109133, ab133243), MCM2 (ab4461), p-SHP2 (ab62322), PCNA (ab2426), and Cleaved caspase-3 (ab2303) were purchased from Abcam. Antibodies against γH2AX (#9718), p-S6RP (#4856, #5364), S6RP (#2317), p-4EBP1 (#9456, #2855, #9455), 4EBP1 (#9644), p-IGF-1R/INSR (#3024), IGF-1R (#9750), p-PDGFRβ (#3161), PDGFRβ (#4564), p-AKT (#4060), and AKT (#2920) were purchased from Cell Signalling. EGFR antibody (610017) was purchased from BD Biosciences. H3K9Me3 antibody (49-1008) and p-EGFR (44-788) were from Thermo Fisher Scientific.
Wang C., Vegna S., Jin H., Benedict B., Lieftink C., Ramirez C., Leite de Oliveira R., Morris B., Gadiot J., Wang W., du Chatinier A., Wang L., Gao D., Evers B., Jin G., Xue Z., Schepers A., Jochems F., Mulero Sanchez A., Mainardi S., te Riele H., Beijersbergen R.L., Qin W., Akkari L, & Bernards R. (2019). Inducing and exploiting vulnerabilities for the treatment of liver cancer. Nature, 574(7777), 268-272.
+ Open protocol
+ Expand
3

3D Keratinocyte Culture with Inhibitors

Check if the same lab product or an alternative is used in the 5 most similar protocols
Exponentially growing keratinocytes maintained in CnT-Prime medium (CELLnTEC, Catalog No. CnT-PR) were detached using Accutase, centrifuged at 300× g for 5 min at room temperature, and counted. A total of 2 × 105 cells were then seeded onto polycarbonate inserts (Thermo Fisher Scientific, Catalog No. 140620) and cultured for two days in CnT-Prime medium. Upon confluency, the medium was changed to 3D-Barrier (CELLnTEC, Catalog No. CnT-PR-3D) and the air-lift performed according to the manufacturer’s instructions. 3D cultures were maintained for 12 days with three medium changes per week. When indicated, the inhibitors and corresponding vehicles were applied in the sixth day after carrying out the airlift and refreshed with the medium changes indicated above. Inhibitors used included Alisertib (Selleckchem, Munich, Germany; Catalog No. S1133), XL413 (Selleckchem, Catalog No. S7547), AZD7762 (Selleckchem, Catalog No. S1532), and BI2536 (Selleckchem, Catalog No. S1109) (10 nM each). Concentrations of inhibitors were selected based on the induction of minor effect in the organotypic structures formed by control cells.
Lorenzo-Martín L.F., Menacho-Márquez M, & Bustelo X.R. (2020). Drug Vulnerabilities and Disease Prognosis Linked to the Stem Cell-Like Gene Expression Program Triggered by the RHO GTPase Activator VAV2 in Hyperplastic Keratinocytes and Head and Neck Cancer. Cancers, 12(9), 2498.
+ Open protocol
+ Expand
4

Western Blot Analysis of Cell Cycle Regulators

Check if the same lab product or an alternative is used in the 5 most similar protocols
AZD‐6783, CCT245737, XL413, TAK‐931, Etoposide were purchased from Selleckchem (Houston, TX, USA). Antibodies used for western blotting include: anti‐Myc (ab32072, 1 : 2000), anti‐CCNE1 (CST #4129, 1 : 1000), anti‐ABCB1 (CST #12683, 1 : 1000), anti‐FBXW7 (Bethyl #A301‐720A, 1 : 1000), anti‐Lamin A/C (CST #4777, 1 : 2000), anti‐Histon 3 (CST #4499, 1 : 1000), anti‐RIF1 (CST #95558, 1 : 1000), anti‐actin (CST #4970, 1 : 2000).
Baxter J.S., Brough R., Krastev D.B., Song F., Sridhar S., Gulati A., Alexander J., Roumeliotis T.I., Kozik Z., Choudhary J.S., Haider S., Pettitt S.J., Tutt A.N, & Lord C.J. (2023). Cancer‐associated FBXW7 loss is synthetic lethal with pharmacological targeting of CDC7. Molecular Oncology, 18(2), 369-385.
+ Open protocol
+ Expand
5

Cisplatin and Etoposide Dissolution Protocol

Check if the same lab product or an alternative is used in the 5 most similar protocols
The Cisplatin (DDP) and Etoposide(VP16)was purchased from Selleck and dissolved in DMSO to a final concentration of 5 mg/ml and 20 mg/ml. The CDC7 inhibitor XL413 was purchased from Selleck and dissolved in ddH2O to a final concentration of 10 mM.
Deng L., Yang L., Zhu S., Li M., Wang Y., Cao X., Wang Q, & Guo L. (2023). Identifying CDC7 as a synergistic target of chemotherapy in resistant small-cell lung cancer via CRISPR/Cas9 screening. Cell Death Discovery, 9, 40.
+ Open protocol
+ Expand
6

Knockdown Studies of Cell Cycle Regulators

Check if the same lab product or an alternative is used in the 5 most similar protocols
Knockdown studies were performed using SMARTpool scrambled control siRNA (Dharmacon), SMARTpool ON-TARGET plus CDC6 siRNA (Dharmacon), SMARTpool ON-TARGET plus CDC45 siRNA (Dharmacon), FlexiTube Hs_CDT1_7 (QIAGEN) and FlexiTube Hs_CDT1_8 (QIAGEN). siRNAs were transfected at 20nM concentration using HiPerFect reagent (QIAGEN) and OptiMEM (Invitrogen). The following small-molecule inhibitors were used at the indicated final concentrations: 50 nM CHIR-124 (CHK1 inhibitor; Selleck Chemicals), 30nM UCN-01 (CHK1 inhibitor; Sigma), 5 uM RO-3306 (Cdk1 inhibitor; Calbiochem), 10 uM NU6140 (Cdk2 inhibitor; Calbiochem), 25uM Roscovitine (Cdk1/2 inhibitor; Selleck Chemicals), 3uM CDK1/2 inhibitor III (Millipore),10 uM SB202190 (p38 inhibitor; Selleck Chemicals), 50 nM BI2536 (PLK1 inhibitor, Selleck Chemicals), 200nM GSK461364 (PLK1 inhibitor; Selleck Chemicals), 2.5 mM Thymidine (Sigma Aldrich), 15 uM XL-413 (CDC7 inhibitor; Selleck Chemicals), 100 nM BMS-650032 (Asunaprevir; Adooq Bioscience), 50 uM 3-Indoleacetic acid (Auxin; Sigma Aldrich), 1ug/ml Doxycycline (Sigma Aldrich).
Lemmens B., Hegarat N., Akopyan K., Sala-Gaston J., Bartek J., Hochegger H, & Lindqvist A. (2018). DNA Replication Determines Timing of Mitosis by Restricting CDK1 and PLK1 Activation. Molecular Cell, 71(1), 117-128.e3.
+ Open protocol
+ Expand
7

Cell Stimulation with Cytokines and Inhibitors

Check if the same lab product or an alternative is used in the 5 most similar protocols
Cells were seeded in 6-well plates or 10-cm dish and allowed to attach overnight. Afterwards, cells were treated with IL-6, TNF-α (Peprotech), XL413 (Selleck), caffeic acid phenethyl ester, or selinexor (MedChem Express) according to the methods described in the text.
Zhang L., Hong J., Chen W., Zhang W., Liu X., Lu J., Tang H., Yang Z., Zhou K., Xie H., Jia C., Jiang D, & Zheng S. (2023). DBF4 Dependent Kinase Inhibition Suppresses Hepatocellular Carcinoma Progression and Potentiates Anti-Programmed Cell Death-1 Therapy. International Journal of Biological Sciences, 19(11), 3412-3427.
+ Open protocol
+ Expand
8

Comprehensive DNA Replication Assay

Check if the same lab product or an alternative is used in the 5 most similar protocols
The following chemical reagents were used throughout the study: AZD6738 (Selleck Chemicals; #S7693), XL413 (Selleck Chemicals; #S7547), B02 (Selleck Chemicals; #S8434), Olaparib (Selleck Chemicals; #S1060), Veliparib (Selleck Chemicals; #S1004), Talazoparib (Selleck Chemicals; #S7048), 5-Iodo-2'-deoxyuridine (IdU) (Millipore Sigma; #I7125), 5-Chloro-2'-deoxyuridine (CldU) (Millipore Sigma; #C6891), Hydroxyurea (Tokyo Chemical Industry; #H0310), Doxycycline (Millipore Sigma; #D1822).
Dibitetto D., Sanchi A., Sanford E.J., Lopes M., & Smolka M.B. (2021). Fork Slowing and Reversal as an Adaptive Response to Chronic ATR Inhibition.
+ Open protocol
+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required

Sign up now

Revolutionizing how scientists
search and build protocols!